NCT04990427View on ClinicalTrials.gov

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

January 26, 2023

Study Completion Date

January 26, 2023

Conditions
Chronic Kidney Diseases
Interventions
DRUG

CLBS201

1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells

Trial Locations (1)

78212

Clinical Advancement Center, PLLC, San Antonio

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT04990427 - CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter